Anti-HGFR / c-Met Reference Antibody (Korea RIBB patent anti-cMet)

Used in targeted cancer therapies, this antibody inhibits the c-Met signaling pathway, which is often overactive in various tumors such as lung, liver, and gastric cancers. It blocks hepatocyte growth factor (HGF)-mediated receptor activation, suppressing tumor growth, invasion, and metastasis. Due to its high specificity, it serves as a key reagent in diagnostic assays and immunohistochemistry for detecting c-Met expression in cancer tissues. It is also employed in research and drug development to evaluate c-Met pathway inhibition and to support the design of new biologics and antibody-drug conjugates.

Mechanism	-
Appearance	-
Longevity	-
Strength	-
Storage	-
Shelf Life	-
Allergen(s)	-
Dosage (Range)	-
Recommended Dosage	-
Dosage (Per Day)	-
Recommended Dosage (Per Day)	-
Mix Method	-
Heat Resistance	-
Stable in pH range	-
Solubility	-
Product Types	-
INCI	-